Search Results

51 - 60 of 564 items :

  • pharmacokinetics x
Clear All
Analytical Methodologies for the Stereoselective Determination of Sibutramine: An Overview

)-sibutramine: comparison with (RS)-sibutramine and (S)-sibutramine. Indian J Physiol Pharmacol. 2007;51(2):175-178. 5. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. - A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21(3):457-468. 6. Glick SD, Haskew RE, Maisonneuve IM, et al. - Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol. 2000;397:93-102. 7. Noh K, Bae K, Min B, et al. - Enantioselective pharmacokinetics of sibutramine in rat. Arch Pharm Res. 2010

Open access
Kinetic Modelling of Drug Release from Pentoxifylline Matrix Tablets based on Hydrophilic, Lipophilic and Inert Polymers

References [1] Costa P, Lobo JMS. Modelling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-133. [2] Kohler AN, Murphree ES. A comparison of the Akaike and Schwarz criteria for selecting model order. Appl Statist. 1998;37:187-195. [3] Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J. Pharmacokinetic Biopharm. 1994;22:431-445. [4] Martindale, The Complete Drug Reference. 37th ed

Open access
Deciphering nifedipine in vivo delivery from modified release dosage forms: Identification of food effect

. EMA/CPMP (2010), Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. 5. EMA/CHMP (2014), Guideline on the Pharmacokinetic and Clinical Evaluation of Modified Release Dosage Forms, EMA/CPMP/EWP/280/96 Corr1. 6. W. Jiang, S. Kim, X. Zhang, R. A. Lionberger, B. M. Davit, D. P. Conner and L. X. Yu, The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation, Int. J. Pharm. 418 (2011) 151-160; DOI: 10.1016/j.ijpharm.2011.07.024. 7. E. S

Open access
In Vitro Interactions of Diclofenac with Several Types of Food

;37:937-945. 5. Gan TJ. - Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26:1715-1731. 6. Davies NM, Anderson KE. - Clinical Pharmacokinetics of Diclofenac. Clin Pharmacokinet. 1997;33:1-20. 7. Hinz B, Chevts J, Renner B, et al. - Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005;59:80-84. 8. Walter K, von Nieciecki A. - Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation with enteric-coated pellets. Arzneimittel-Forschung-Drug Res

Open access
Therapeutic Drug Monitoring in Rheumatic Diseases

1 Introduction The main goal of treating rheumatic diseases is to achieve rapid and effective suppression of inflammation. More and more drugs have been proven to be able to achieve these goals nowadays. The current practice is to give a recommended dose of drugs to our patients according to the body weight, risk factors and tolerance, etc. However, all our patients are different individuals who have different pharmacokinetics, and this difference in pharmacokinetics can affect the true drug concentration that is working inside them. This may create

Open access
Determination of Free Doxycycline Concentrations in the Plasma and Milk of Sheep and in the Plasma of Rabbits by using the HPLC Method

REFERENCES 1. Chopra, I., Roberts, M. (2001). Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 65 (2): 232-260. https://doi.org/10.1128/MMBR.65.2.232-260.2001 PMid:11381101 PMCid:PMC99026 2. Valentín, S., Morales, A., Sánchez, J.L., Rivera, A. (2009). Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2, 129-140. PMid:21436975 PMCid:PMC3047926 3. Agwuh, K. N., MacGowan, A. (2006). Pharmacokinetics and

Open access
The problem of low peak concentration of gentamicin in clinical practice

W., T. - CANADAY, B., R. - POE, T., E.: Variables affecting creatinine prediction. Am J Hosp Pharm 40, 12, 1983, p. 2175 - 90. EVANS, W., E -OELRICH, M. - HOLTZ, D., W.: Therapeutic Drug Monitoring. Clinical Guide. 2 ed. Wiesbaden, Germany. ABBOTT Laboratory, Diagnostic Division, 1994, 160 p. MURPHY, J., E.: Clinical Pharmacokinetics. 4 th edition Bethesda, Maryland: American Society Health - System Pharmacists, Publishing, 2008, p. 463. DESOKY, E., E. - KLOTZ, U.: Value, limitations

Open access
CYP3A5 Polymorphism In Serbian Paediatric Epileptic Patients On Carbamazepine Treatment

, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014; 37C:59-70. 6. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50(1):1-23. 7. Thorn CF, Leckband SG, Kelsoe J, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011; 21(12):906-10. 8. Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol

Open access
Formulation Studies of Solid Self-Emulsifying Drug Delivery System of Ivermectin

improved dosing schedule for ivermectin as a microfilaricidal agent against onchocerciasis. Acta Trop 1997;68(3):269-75. 5. Camargo JA, Sapin A, Nouvel C, et al. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physicochemical characterization. Drug Dev Ind Pharm 2013;39(1):146-55. 6. Canga AG, Sahagun Prieto AM, Diez Liebana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J 2008;10(1):42-6. 7. Chaudhari PD, Motewar PP, Sherekar

Open access
Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay / Determinarea rapidă a apixabanului în plasma umană prin cromatografie de lichide de înaltă performanță cuplată cu spectrometrie de masă în tandem

.1097/ ALN.0b013e318289bcba 9. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anesthesia and antithrombotic agents: recommendations of the European society of Anaesthesiology. Eur J Anaesthesiol. 2010 Dec;27(12):999-1015. DOI: 10.1097/ EJA.0b013e32833f6f6f 10. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013 Feb;75

Open access